To define the factors associated with methotrexate (MTX) resistance in patients with low-risk gestational trophoblastic neoplasia (GTN).
A total of 63 patients with low-risk GTN according to International Federation of Gynecology and Obstetrics (FIGO) criteria were included. A total of 37 (58.7%) patients were treated with successive doses of 1 mg/kg intramuscular (IM) MTX on days 1, 3, 5, and 7, and 0.1 mg/kg IM folinic acid (FA) on days 2, 4, 6, and 8, until β-human chorionic gonadotropin (hCG) levels were normalized. After the β-hCG value dropped to the normal level, an additional cycle of MTX/FA was administered. This protocol is defined as the standard protocol. In a watchful waiting protocol, the same 8-day IM MTX/FA regimen was given only once (n = 8) or twice (n = 18) to 26 (41.3%) patients and patients in whom β-hCG values declined were subjected to follow-up and no additional cycles were administered as long as there was a decrease in β-hCG value. Clinical response and factors affecting therapeutic outcomes were analyzed retrospectively.
Of 63 patients, 47 (74.3%) were cured with primary MTX/FA treatment irrespective of any protocol. Of the 16 patients who were not able to be treated with primary MTX/FA, 3 were treated with single-agent actinomycin-D and 11 were treated with multi-agent chemotherapy. Univariate analysis showed that a pretreatment β-hCG level of ≥5000 IU/L was related to reduced therapeutic response (p = 0.001). The FIGO score, antecedent gestational pathology, and treatment with standard or watchful waiting protocol were not related to treatment response.
The level of β-hCG prior to therapy is an important factor for predicting therapeutic outcomes. It should be noted that the success of the therapy decreases notably in case of high β-hCG level.
Tumori 2017; 103(2): 177 - 181
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsOsman Turkmen, Derman Basaran, Alper Karalok, Gunsu Comert Kimyon, Tolga Tasci, Isin Ureyen, Gokhan Tulunay, Taner Turan
- • Accepted on 13/07/2016
- • Available online on 04/08/2016
- • Published in print on 24/03/2017
This article is available as full text PDF.
- Turkmen, Osman [PubMed] [Google Scholar] , * Corresponding Author (email@example.com)
- Basaran, Derman [PubMed] [Google Scholar]
- Karalok, Alper [PubMed] [Google Scholar]
- Kimyon, Gunsu Comert [PubMed] [Google Scholar]
- Tasci, Tolga [PubMed] [Google Scholar]
- Ureyen, Isin [PubMed] [Google Scholar]
- Tulunay, Gokhan [PubMed] [Google Scholar]
- Turan, Taner [PubMed] [Google Scholar]
Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women’s Health Teaching and Research Hospital, Ankara - Turkey